Biopharma-focused hedge funds have cut back sharply on their private venture capital investments in 2022, but not to the extent of the tech-focused firms. Yes, they all participated in fewer private fundraisings
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.